With inflation risks, shifting interest rate paths and geopolitical tensions all in focus, many investors are looking for companies that analysts expect to grow earnings while keeping their balance sheets in reasonable shape. That is exactly what the Healthy high growth potential screener aims to highlight by filtering for stocks where analysts see strong earnings growth over the next 3 years and an acceptable financial position. In this article, you will see 3 stocks selected from this screener that can help you focus on growth potential without ignoring financial health.
Columbia Financial (CLBK)
Overview: Columbia Financial is a New Jersey based community-focused bank holding company that offers a wide range of lending, deposit, wealth management and cash management services to both businesses and households through its Columbia Bank branch network.
Operations: Columbia Financial generates about US$259.2m in revenue entirely from financial services in the United States.
Market Cap: US$3.0b
Columbia Financial stands out in this screener because analysts expect strong earnings and revenue growth while the bank is in the middle of a major transformation into a fully public company with the Northfield Bancorp acquisition. The enlarged group is expected to become one of the region’s larger community banks, with over 100 branches and a broader customer base. This scale can be important for growing revenue and fee income. At the same time, the stock trades on a high P/E multiple and has seen substantial equity dilution and share price volatility, so expectations are already elevated and execution is important. For investors who are comfortable assessing growing banks, Columbia Financial presents a mix of growth ambitions, recent profitability and structural change that may warrant closer attention.
Columbia Financial is transforming into a larger community bank while carrying a high P/E. The real question is whether growth expectations match reality, and how the analyst forecasts for Columbia Financial handles the dilution story investors often miss
Insulet (PODD)
Overview: Insulet is a medical device company that makes tubeless insulin delivery systems, including the Omnipod 5 automated insulin pump that works with continuous glucose monitors, helping people with insulin dependent diabetes manage blood sugar more easily in the US and abroad. It also supplies wearable drug delivery pods for partners such as Amgen for use after chemotherapy.
Operations: Insulet generates about US$2.9b in revenue from drug delivery systems, with roughly US$2.1b coming from the United States and US$844.9m from international markets.
Market Cap: US$11.3b
Insulet catches the eye in this screener because its Omnipod platform ties recurring pod sales to growing adoption of automated insulin delivery. Analysts currently expect strong earnings and revenue growth as the company expands in type 2 diabetes and additional international markets. At the same time, reliance on a single product family, recent product recalls, and legal actions around manufacturing controls highlight meaningful execution and regulatory risk. Net margins currently sit around 10.4% and returns on equity are high. Together with broad reimbursement and pharmacy distribution, these factors underline a business with attractive economics but a valuation that already reflects substantial anticipated success. For investors, the key question is whether Omnipod’s growth and margin profile can continue to outweigh these risks.
Insulet’s Omnipod story looks powerful, but the real tension is how far expectations can stretch before risk starts to bite. Study the analyst forecasts for Insulet to see what the current optimism might be missing.
Hamilton Lane (HLNE)
Overview: Hamilton Lane is a Philadelphia based asset manager that helps institutions and wealthy individuals invest in private markets, running private equity and credit funds, evergreen products and tailored accounts across regions such as the US, Europe and Asia.
Operations: Hamilton Lane generates about US$759.0m in revenue from asset management, with roughly US$310.4m from the United States and US$448.6m from other countries.
Market Cap: US$4.7b
Hamilton Lane stands out in this screener because its fee based model on private markets assets, a reported unrealized carry pool of about US$1.3b, and a pipeline of evergreen and customized funds all indicate a business with meaningful embedded revenue potential. At the same time, the company depends on external borrowing, faces regulatory and fee pressure, and is operating in a competitive space where investor preferences can shift quickly. For readers, the puzzle is how to weigh these cash flow drivers and dividend growth against the funding structure and the evolving private markets backdrop, and whether the current P/E and analyst targets still leave a reasonable margin of safety.
Hamilton Lane’s fee based cash flows and unrealized carry pool hint at earnings power that many investors may be underestimating, but the funding mix and private markets cycle could be the real swing factor. As a result, the analysis report for Hamilton Lane cuts to the trade off that may matter most next.
The three stocks here are just a starting point. The full Healthy high growth potential screen surfaces 254 more companies that analysts expect to grow earnings strongly while keeping balance sheets in acceptable shape through the Healthy high growth potential screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction opportunities within this group.
Take Control of Your Investment Journey
If Insulet or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Seeking Fresh Alternatives Before They Fly?
Markets move fast, and the next breakout list can stop looking cheap once momentum takes hold. Scan these fresh ideas under the radar for now, then act based on your own research and judgment.
- Spot companies quietly building strength before attention catches up by scanning the 81 resilient stocks with low risk scores that still show room to move while risk stays contained.
- Ride structural themes with clear earnings stories by checking the curated 63 profitable AI stocks that aren't just burning cash where cash generation already backs the AI narrative.
- Target income opportunities while prices are still moving in and out of favor by reviewing the hand-picked 7 dividend fortresses built around high-yield resilience.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com